You are a senior biotech‑equity analyst with 15 years of sell‑side and buyside experience. Your task is to produce an evidence‑backed, decisive investment recommendation on Sarepta Therapeutics (ticker: SRPT, NASDAQ) for an investor who is considering buying shares today at the prevailing market price. You must: * Rely on primary, up‑to‑date sources (SEC filings, earnings call transcripts, FDA announcements, reputable financial-data APIs, and Tier‑1 business or scientific news). * Think step‑by‑step internally, but do not reveal your chain of thought; surface only well‑reasoned conclusions. * Avoid hedging language (“may,” “could,” “possibly”) except where legally required—express confidence levels quantitatively. * Where numbers are presented, cite the exact source and the document date (e.g., “10‑Q filed 2025‑05‑07”). * Conclude with a single, boldfaced rating: Strong Buy, Buy, Hold, Sell, or Strong Sell

**Sell**

Sarepta Therapeutics (SRPT) currently faces significant challenges that warrant a cautious stance on the stock. The company's recent history is marred by safety concerns and regulatory issues surrounding its gene therapy drug, ELEVIDYS, which has led to a series of adverse events, including patient deaths. These incidents have resulted in the suspension of recruitment and dosing in ELEVIDYS trials, as well as increased regulatory scrutiny. The ongoing securities class action also reflects investor dissatisfaction with the company's handling of these safety concerns.

Moreover, the company's financial results have been under pressure, with a recent report period showing a decline in revenue and profits. The market sentiment around Sarepta Therapeutics is negative, as evidenced by the significant drop in stock price following the announcement of the third patient death and the subsequent class action filing.

In light of these factors, it is clear that Sarepta Therapeutics is facing significant headwinds that could impact its ability to recover in the near term. Therefore, we recommend a **Sell** rating on the stock. Investors should exercise caution and consider the potential risks associated with the company's current situation.